Data alert

Preventing stroke in AF: New data on role of antithrombotic therapy

All forms of atrial fibrillation (AF), whether permanent, persistent, or paroxysmal, are associated with an increased risk of stroke and antithrombotic therapy is recommended for almost all AF patients.1 Current guidelines are likely to evolve in response to studies that have appeared in the past year. This Data Alert reviews these studies as well as ongoing studies that also may influence clinical practice.

References are listed at the end of the Data Alert.

High incidence of asymptomatic AF

Download DA%20antithrombotic%20therapy.ppt (6 slides - 0.1MB)

High incidence of asymptomatic AF High incidence of asymptomatic AF: Clinical implications Warfarin increases hemorrhagic stroke mortality Trials of emerging antithrombotic therapiesfor stroke prevention in AF SPORTIF III and V pooled results:
Primary outcome SPORTIF III and V pooled results:
Net clinical benefit
Data_Alert.pdf (0.5MB)Data_Alert.pdf (0.5MB)


Related at vwbg.org

Results from CRUSADE: Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the American College of Cardiology/American Heart Association Guidelines

CRUSADE investigated the association between dosing levels of antithrombotic agents and bleeding, in-hospital mortality, and length of stay in patients with NSTE ACS.

Expanding opportunities for secondary prevention of stroke

Between 1979 and 2001, the number of patients discharged from the hospital with a primary diagnosis of stroke increased by 25%.
More related